Home
HelpTest Code C199 Carbohydrate Antigen 19-9 (CA 19-9)
Specimen Type
Blood
Container
Mint green top with gel separator
Preferred Volume
3.5 mL
UCMC Collection Instructions
Once per admit. If serial monitoring needed, Q daily.
Availability
Monday – Friday 7:00 a.m. – 6:00 p.m.
Turnaround Time
24 – 72 hrs
STAT Availability
Not Available
Test Usage
Immunoassay for the in vitro quantitative determination of CA 19-9 tumor associated antigen, in human serum and plasma. The assay is indicated for the serial measurement of CA 19-9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in the monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of CA 19-9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort.
Test Methodology
Roche Elecsys CA 19-9, Electrochemiluminescence Immunoassay (ECL)
Additional Information
The measured CA 19-9 value of a patient’s sample can vary
depending on the testing procedure used. CA 19-9 values
determined on patient samples by different testing procedures
cannot be directly compared with one another and could be the cause
of erroneous medical interpretations.
Patients known to be genotypically negative for Lewis blood group
antigens will be unable to produce the CA 19-9 antigen even in the
presence of malignant tissue. Phenotyping for the presence of the
Lewis blood group antigen may be insufficient to detect true Lewis
antigen negative individuals. Even patients who are genotype
positive for the Lewis antigen may produce varying levels of CA
19-9 as the result of gene dosage effect.
CPT Code
86301
Test Includes
CA 19-9
Critical Results
None
Reference Range
< 37 U/mL
Coverage Information
CMS has established a national coverage policy (NCD) for Medicare for this test as of November 25, 2002. Please document medical necessity. For more details click this link:
Minimum Volume
2 mL
Fee Code
43298
Synonyms
CA 19-9